明德生物(002932.SZ)半年度淨利潤預增347%-471%
格隆匯 7 月 9日丨明德生物(002932.SZ)公佈,預計2020年半年度歸屬於上市公司股東的淨利潤1.8億元-2.3億元,同比增長347%-471%。
2020年上半年,新冠疫情爆發,公司處於疫情中心的武漢市,疫情期間公司迅速反應,竭盡全力克服負面影響支持研發和生產,及時推出了新型冠狀病毒核酸檢測試劑盒,在取得相應註冊證以後,公司的新型冠狀病毒核酸檢測試劑盒在全國多個省市和地區中標,取得了良好的銷售成績。同時,公司的新型冠狀病毒核酸檢測試劑盒和新型冠狀病毒抗體檢測試劑盒還分別取得了歐洲CE、澳大利亞TGA和巴西ANVISA的認證,公司產品銷往國外五十多個國家。此外,疫情檢測相關的儀器銷售業務也增長明顯;
公司全資子公司武漢明志醫學檢驗實驗室有限公司為武漢市定點的核酸檢測機構之一,在此次疫情中承擔了武漢市疫情檢測任務的重要工作,相關的檢測服務收入也大幅增加;
公司積極參與各地PCR實驗室的建設項目,盡力為疫情的防控做全方位的服務;
新冠疫情在二季度逐步緩解,公司原有的非新冠檢測產品的銷售也逐步恢復正常。同時,公司在產品體系上也進行了優化,形成了多產品線檢測及醫療服務方案的系統性產品體系,研發成果也不斷推陳出新,產生了新的收入來源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.